Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3639036 | 0.91 | GRK2 (0.46) | FFAR1FFAR4CACNA1BALDH1A1LMNA | |
| SCHEMBL3641130 | 0.86 | NR1H4 (0.46) | NR1H4GAAALDH1A1KMT2AMAPT | |
| SCHEMBL3637346 | 0.84 | KMT2A (0.42) | NR1H4CACNA1BGAAALDH1A1KMT2A | |
| SCHEMBL3640227 | 0.84 | NR1H4 (0.45) | NR1H4GAAALDH1A1KMT2AMAPT | |
| SCHEMBL3640854 | 0.83 | MAPT (0.49) | KMT2AMAPTMEN1FLT1LMNA | |
| SCHEMBL3640828 | 0.81 | KDM4E (0.47) | FFAR1NR1H4KMT2AMAPTMEN1 | |
| SCHEMBL3636270 | 0.81 | MAPT (0.47) | GAAALDH1A1KMT2AMAPTMEN1 | |
| SCHEMBL3641293 | 0.80 | POLB (0.46) | GAAALDH1A1KMT2AMAPTMEN1 | |
| SCHEMBL3641222 | 0.80 | HPGD (0.43) | NR1H4ALDH1A1KMT2AMAPTMEN1 | |
| SCHEMBL3635764 | 0.80 | MAPT (0.44) | ALDH1A1KMT2AMAPTMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242933-B2 | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-26 | — | — | US | disclosed |
| EP-2167464-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) | Abbott GmbH & Co. KG (DE) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008145616-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) | ABBOTT GMBH & CO. KG (DE) | 2008-12-04 | — | — | WO | disclosed |
| US-20080300260-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300260-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) | GRM2, GRIN2C, GRM1 | FFAR1 173/4885FFAR4 242/4885BTK 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.